Europe
MDxHealth SA, a commercial-stage innovative molecular diagnostics company, provided a business update for the first quarter ended March 31, 2019.
ADC Therapeutics to develop next-generation masked antibody drug conjugates (ADCs), incorporating Adagene’s SAFEbody™ technology, with potential utility across multiple tumor types
Companies across Europe and Asia provide information about deal, clinical trials and more, with news from Synaptive Medical, Epic, Inventiva, Velabs, and more.
Researchers at Sweden’s Lund University reported that a blood test can reveal whether there is accelerating nerve cell damage in the brain.
Cambridge, Mass.-based Fulcrum Therapeutics just acquired a worldwide license with GlaxoSmithKline (GSK) to develop and commercialize losmapimod.
For the past nine years, Saynor has been with GSK, most recently serving as senior vice president and global head of classic and established medicines.
ADC Therapeutics, based in Lausanne, Switzerland, and Adagene, headquartered in Suzhou, China and San Francisco, announced a discovery collaboration and license deal.
MorphoSys AG, Galapagos NV and Novartis Pharma AG announced the initiation of GECKO, a phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
Galapagos NV, MorphoSys AG and Novartis Pharma AG announced the initiation of GECKO, a Phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
Karolinska Development AB announces that its portfolio company Dilafor AB has completed a capital raising and is planning to start a new Phase 2b study of tafoxiparin to soften the cervix prior to labor induction.
PRESS RELEASES